Peroxisome proliferator-activated receptor agonist rosiglitazone improves host defense against Pseudomonas aeruginosa in a murine model of pneumonia
- Crisitina Lyra Nagae1,
- Cassiano Felippe Gonçalves-de-Albuquerque1,
- Alessandra Silveira Ferreira1,
- Raysa Captivo1,
- Larissa Camisão1,
- Carlos André Mandarino Silva1,
- Mirian Priscila Lins de Lima1,
- Caroline Loureiro Hildebrandt1,
- Patricia Torres Bozza1,
- Hugo Caire de Castro-Faria-Neto1 and
- Adriana Ribeiro Silva1
© Nagae et al.; licensee BioMed Central Ltd. 2013
Published: 5 November 2013
Pseudomonas aeruginosa is a Gram-negative bacterium regarded as an opportunistic pathogen. It infects immunocompromised patients, and is the second leading cause of nosocomial diseases. This bacterium has numerous virulence factors, adapts quickly to new environments, and requires a few nutrients to survive. All of these mechanisms will generate a host response. The fastest immune response is neutrophil recruitment, followed by phagocytosis and degranulation. There is another mechanism to fight bacteria called NET formation, which is the formation of a neutrophil extracellular network. NET is formed through a process called NETosis where the release of the cell nuclear material can hold and destroy pathogens. The nuclear receptor peroxisome proliferator-activated receptor PPARγ, besides lipid and glucose metabolism, is involved in the inflammatory response modulation, being considered a potential target for the study of new therapies for inflammatory and infectious diseases. We therefore aim to investigate the involvement of PPARγ in lung injury caused by P. aeruginosa using an agonist of this receptor, rosiglitazone.
Materials and methods
For this purpose, Swiss mice were instilled intratracheally with bacteria and treated with rosiglitazone 5 hours after the operation. We analysed clinical signs using 10 physical parameters, cellularity and DNA measurement to assess NET formation.
We found that the animals stimulated with Pseudomonas showed an increase in inflammatory parameters, while the animals treated with rosiglitazone showed improvement in clinical signs and increased NET formation.
We can conclude that rosiglitazone has an anti-inflammatory role during lung infection, suggesting that PPARγ activation may improve the host defense against bacteria.
Financial support: FIOCRUZ, CNPq and FAPERJ.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.